[1] Vallance
P, Leone A, Calver A, et al. Accumulation of an endogenous inhibitor of nitric
oxide synthesis in chronic renal failure[J].Lancet,1992,339(8793):572-575.
DOI:10.1016/0140-6736(92)90865-z.
[2] 袁美杰,吴明,叶朝阳. 不对称二甲基精氨酸在慢性肾脏病中的作用与机制研究进展[J]. 中国血液净化,2020,19(5):327-329.DOI:10.3969/j.issn.1671-4091.
2020.05.011.
[3] 刘国栋,王桦,汪琦,等. APOE基因多态性与血脂异常相关性分析[J]. 武汉大学学报(医学版),2017,38(2):267-270.
DOI:10.14188/j.1671-8852.2017.02.020.
[4] Boerwinkle E, Visvikis S, Welsh D, et
al. The use of measured genotype information in the analysis of quantitative
phenotypes in man. II. The role of the apolipoprotein E polymorphism in
determining levels, variability, and covariability of cholesterol,
betalipoprotein, and triglycerides in a sample of unrelated individuals[J]. Am
J Med Genet,1987,27(3):567-582. DOI:10.1002/ajmg. 1320270310.
[5] 梁爱芬,何韶坚,华仙丽,等. ApoE基因多态性与慢性心血管疾病及患者血脂水平的相关性研究[J]. 国际检验医学杂志,2017,38(12):1601-1602,1605.
DOI:10.3969/j.issn.1673- 4130. 2017. 12.006.
[6] Wieczorek-Surdacka E, Hanff E, Chyrchel
B, et al. Distinct associations between plasma osteoprotegerin, homoarginine
and asymmetric dimethylarginine in chronic kidney disease male patients with
coronary artery disease[J].Amino Acids,2019,51(6):977-982. DOI:10.1007/s00726-
019-02738-x.
[7] Ravani P, Tripepi G, Malberti F, et al.
Asymmetrical dimethylarginine predicts progression to dialysis and death in
patients with chronic kidney disease: a competing risks modeling approach[J].J
Am Soc Nephrol,2005,16(8):2449-2455. DOI:10.1681/ASN.2005010076.
[8] Wang C, Jiang H, Jin J, et al.
Development of potent type I protein arginine methyltransferase (PRMT)
inhibitors of leukemia cell proliferation[J].J Med Chem,2017,60(21):8888-8905.
DOI:10.1021/acs.jmedchem.7b01134.
[9] 温佐强,魏昕,方才. 不对称二甲基精氨酸和内皮细胞功能紊乱及相关疾病的关系[J]. 安徽医药,2009,13(1):13-15.
DOI:10.3969/j.issn.1009-6469.2009.01.006.
[10] Sibal L, Agarwal SC, Home PD, et al. The
role of asymmetric dimethylarginine (ADMA) in endothelial dysfunction and
cardiovascular disease[J].CurrCardiol Rev,2010,6(2):82-90.
DOI:10.2174/157340310791162659.
[11] Park MJ, Oh KS, Nho JH, et al.
Asymmetric dimethylarginine (ADMA) treatment induces apoptosis in cultured rat
mesangial cells via endoplasmic reticulum stress activation[J].Cell Biol
Int,2016,40(6):662-670. DOI:10.1002/cbin.10602.
[12] Zhou TB, Qin YH, Xu HL. Association of
apoE gene expression and its gene polymorphism with nephrotic syndrome
susceptibility: a meta-analysis of experimental and human studies[J].MolBiol
Rep,2012,39(10):9347-9354. DOI:10.1007/s11033-012-1751-4.
[13] 胡耀,谭昀,桂绍涛,等. 高血脂病人载脂蛋白E基因多态性与心肌梗死相关性[J]. 安徽医药,2020,24(9):1753-1756. DOI:10.3969/j.issn.1009-6469.2020.09.014.
[14] 董政,娄焕堃,梅佳慧,等. 载脂蛋白E基因多态性与炎症的相关性研究进展[J]. 中国临床实用医学,2020,11(5):74-77. DOI:10.3760/cma.j.cn115570-20200715.01006.
[15] 汪明琅,娄焕堃,王飞翔,等. ApoE基因多态性与心房颤动的相关性研究[J]. 国际医药卫生导报,2019,25(22):3680-3684.
DOI:10.3760/cma.j.issn.1007-1245.2019. 22.006.
[16] Bennet AM, Di Angelantonio E, Ye Z, et
al. Association of apolipoprotein E genotypes with lipid levels and coronary
risk[J].JAMA,2007,298(11):1300-1311. DOI:10.1001/jama.298.11.1300.
[17] 张秀玲. 山东汉族人群ApoE基因多态性与房颤的相关性[D]. 济南:山东大学,2017.
[18] Liberopoulos E, Siamopoulos K, Elisaf M.
Apolipoprotein E and renal disease[J].Am J Kidney Dis,2004,43(2):223-233. DOI:10.1053/j.ajkd.2003.10.013.
[19] Xue C, Nie W, Tang D, et al.
Apolipoprotein E gene variants on the risk of end stage renal disease[J].PLoS
One,2013,8(12):e83367. DOI:10.1371/journal.pone.0083367.
[20] Hubacek JA, Bloudickova S, Kubinova R,
et al. Apolipoprotein E polymorphism in hemodialyzed patients and healthy
controls[J].Biochem Genet,2009,47(9-10):688-693. DOI:10.1007/s10528-009-9266-y.
[21] Roussos L, Ekström U, Ehle PN, et al.
Apolipoprotein E polymorphism in 385 patients on renal replacement therapy in
Sweden[J].Scand J Urol Nephrol,2004,38(6):504-510.
DOI:10.1080/00365590410033443.
|